ReviewHistology and histopathology2026
Glutamate signaling and transport around nodes of Ranvier and internodal myelin regions.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The roles of glutamate as a major building block of proteins and as a key participant in numerous metabolic pathways are well established. Likewise, glutamate's function as a neurotransmitter-along with the distribution and actions of its receptors and reuptake mechanisms within the brain's gray matter-has been extensively characterized, leading to the development of existing and emerging treatments for neurological and psychiatric disorders. More recently, it has become clear that glutamate is also released in significant amounts within the white matter (WM), where it acts on specific receptors and is taken up by dedicated transporters. In the WM, glutamate is essential for activating receptors that support the development and maintenance of myelinated axons. Growing evidence further indicates that elevated extracellular glutamate or impaired glial reuptake in the WM can lead to pathological outcomes. Many of the receptors and transporters involved in glutamate signaling are located on astrocytic membranes and on the oligodendrocyte-derived myelin sheath, particularly concentrated at nodes of Ranvier and the adjacent paranodal and juxtaparanodal regions. This expanding understanding of glutamate-related mechanisms in the WM may ultimately pave the way for new therapeutic strategies targeting WM pathologies.
Indexed as
Identifiers
42011110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.